Needham Reiterates Buy Rating on MapLight Therapeutics
Needham maintains its buy rating with a $42 price target for MapLight Therapeutics, a 39.77% upside from the current price.
Key Points
- Needham reiterated its buy rating on MapLight Therapeutics (MPLT) with a $42 price target on June 22, 2026.
- Needham's $42 price target implies 39.77% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $30.05 share price.
- Shares of MPLT traded near $30.47 on Tuesday, with a 52-week range of $12.24 to $33.28 and a market cap of about $1.35 billion.
- Analysts from firms like Stifel and UBS also have buy ratings, with price targets ranging from $36 to $48.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Needham reiterated its buy rating for MapLight Therapeutics, Inc. (NasdaqGS: MPLT), setting a price target of $42. Analyst Ami Fadia maintained this optimistic outlook as the stock traded around $30.47 on Tuesday.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
MapLight Therapeutics, Inc. Stock Up 138.5%
Shares of MapLight Therapeutics were trading near $30.47 on Tuesday. The company, with a market capitalization of approximately $1.35 billion, operates in the biotechnology sector, focusing on treatments for central nervous system disorders. The stock's 52-week range spans from $12.24 to $33.28, with a 50-day moving average of $28.92 and a 200-day moving average of $21.11. MapLight has a high current ratio of 22.91 and a quick ratio of 21.71, reflecting strong liquidity.
$MPLT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 22, 2026, Needham maintained its buy rating and set a $42 price target for MapLight Therapeutics. Earlier in the month, Stifel also maintained a buy rating with a $36 target on June 2. UBS initiated coverage with a buy rating and a $48 target on May 27, while Craig-Hallum also initiated with a buy rating and a $43 target on May 21. Overall, the consensus among analysts is a buy rating, with a mean price target of $38.7 based on 10 analyst opinions.
About MapLight Therapeutics
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Redwood City, California. Led by CEO Dr. Christopher A. Kroeger, the company employs 133 people and focuses on developing therapies for debilitating central nervous system disorders. Its pipeline includes treatments for schizophrenia, Alzheimer's disease psychosis, autism spectrum disorder, Parkinson's disease, and other neuropsychiatric conditions.
Bottom Line
Needham's reiterated buy rating and $42 price target for MapLight Therapeutics highlight ongoing confidence in the company's potential. Investors are closely watching its progress in the biotechnology sector. As with all 13F filings and analyst ratings, these insights reflect past data and sentiment, and may not indicate current or future performance.
Get MapLight Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MPLT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.